Stephen J. Forman - 30 Jun 2023 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role
Director
Signature
/s/ Stephen Forman
Issuer symbol
LIXT
Transactions as of
30 Jun 2023
Net transactions value
$0
Form type
4
Filing time
07 Jul 2023, 10:55:50 UTC
Previous filing
03 Aug 2022
Next filing
02 Jul 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIXT Options to Purchase Common Stock Award $0 +10,000 $0.000000 10,000 30 Jun 2023 Common 10,000 $5.88 Direct F1
holding LIXT Options to Purchase Common Stock 10,000 30 Jun 2023 Common 10,000 $7.45 Direct
holding LIXT Options to Purchase Common Stock 10,000 30 Jun 2023 Common 10,000 $30.30 Direct
holding LIXT Options to Purchase Common Stock 5,000 30 Jun 2023 Common 5,000 $32.10 Direct
holding LIXT Warrants to Purchase Common Stock 2,105 30 Jun 2023 Common 2,105 $57.00 By Stephen Forman Living Trust
holding LIXT Options to Purchase Common Stock 833 30 Jun 2023 Common 833 $9.00 Direct
holding LIXT Options to Purchase Common Stock 833 30 Jun 2023 Common 833 $66.00 Direct
holding LIXT Warrants to Purchase Common Stock 1,667 30 Jun 2023 Common 1,667 $60.00 By Stephen Forman Living Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective June 30, 2023, the reporting person was granted stock options to purchase an aggregate of 10,000 shares, vesting on the last day of each subsequent quarter until fully vested (e.g. vesting to start on September 30, 2023). Effective June 2, 2023, the Issuer effected a 1-for-10 reverse split of its outstanding shares of common stock. Accordingly, the exercise price and the amount of underlying shares of Common Stock set forth above have been adjusted to reflect the reverse split.